
This report presents a guide to selecting high-quality commercial antibodies against Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2/B1) by immunoblot (Western blot), immunoprecipitation and immunofluorescence, using a knockout based validation approach. This study was funded in part by the ALS-Reproducible Antibody Platform (ALS-RAP), established as a public-private partnership by three prominent ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
P22626, antibody characterization, Western Blot, HNRNPA2B1, immunoprecipitation, RNA-binding, ribonucleoprotein, immunoblot, immunofluorescence, antibody validation, Heterogeneous nuclear ribonucleoproteins A2/B1, hnRNP A2/B1, hnRNP
P22626, antibody characterization, Western Blot, HNRNPA2B1, immunoprecipitation, RNA-binding, ribonucleoprotein, immunoblot, immunofluorescence, antibody validation, Heterogeneous nuclear ribonucleoproteins A2/B1, hnRNP A2/B1, hnRNP
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
